Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus...

Area of Science:

• Microbiology
• Immunology
• Pulmonary Medicine

Background:

• Bronchiectasis and refractory Mycobacterium abscessus lung disease present significant treatment challenges.
• Phage therapy is an emerging alternative for managing difficult-to-treat bacterial infections.

Observation:

• A case study involved an 81-year-old immunocompetent patient with bronchiectasis and refractory Mycobacterium abscessus lung disease.
• The patient received a three-phage cocktail administered intravenously for six months.

Findings:

• Intravenous phage administration was safe and reduced Mycobacterium abscessus sputum load by tenfold within one month.
• Therapeutic efficacy was limited after two months due to the development of a robust IgM- and IgG-mediated neutralizing antibody response to the phages.

Implications:

• This case highlights the potential of phage therapy in treating Mycobacterium abscessus lung disease.
• The development of neutralizing antibodies against bacteriophages can limit their long-term therapeutic efficacy.
• Further research is needed to overcome antibody-mediated resistance in phage therapy.